Biomarker ID | 1979 |
PMID | 22589488 |
Year | 2012 |
Biomarker | Methylation status of HS3ST2 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethlated in Recurrent prostate cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Recurrent prostate cancer Vs nonrecurrent cancer |
Type of Biomarker | Prognostic |
Cohort | Recurrence (n = 123) versus nonrecurrence (n = 75) |
Senstivity | Training: 65.3 (55.0–74.6); validation: 65.0 (40.8–84.6) |
Specificity | Training: 75.0 (62.1–85.3); validation:60.0 (36.0–80.9) |
AUC | Training: 0.798; validation:0.733 |
Accuracy | NA |
Level Of Significance | <0.0001 |
Method Used | Pyrosequencing |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | HS3ST2 |